MAP2K7 and melanoma: Given the diverse resistance mechanisms to both MEK/ERK inhibition, a drug that can inhibit MAPK inhibitor-resistant melanomas, regardless of the resistance mechanism(s), offers a therapeutic advantage in the clinic.